HeartNCT07417748
Kinesthetic Exercises on Adults
A study testing Kinesthetic brain exercises, Cardiorespiratory Physiotherapy and Heart Failure drugs in people with Heart, run by Ege University at 1 site in Turkey (Türkiye).
Trial summary
The aim of this study is to determine the possible effect of kinesthetic brain exercises on cognitive function in patients with heart failure. The study will include 40 volunteer individuals aged 30-65 years who have been diagnosed with heart failure in the Cardiology Department and are followed up with a… Read more about this study
- Who is it for?
- Ages 30 to 65 years
- Conditions the study is for
- Heart
- What is being tested?
- Kinesthetic brain exercises, Cardiorespiratory Physiotherapy and Heart Failure drugs
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 11 Feb 2026to 15 Oct 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosed with heart failure
- Between 30-65 years of age
- No history of cardiac surgery
- Cooperative patients
Who cannot join
- Diagnosed with or having a history of neurological disease
- Pregnant or suspected of being pregnant
- Scoring above 24 on the Mini Mental Test
- Patients for whom exercise is contraindicated
- Individuals with a history of orthopedic surgery
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Effect of Kinesthetic Brain Exercises on Cognitive Function in Patients With Heart Failure
The aim of this study is to determine the possible effect of kinesthetic brain exercises on cognitive function in patients with heart failure.
The study will include 40 volunteer individuals aged 30-65 years who have been diagnosed with heart failure in the Cardiology Department and are followed up with a physiotherapy program. Individuals will be randomized into a kinesthetic brain exercise program group (n=20) and a control group (n=20).
The control group will receive routine medication monitoring as well as a routine physiotherapy program. The education group will receive routine medication monitoring and a routine physiotherapy program, in addition to individual kinesthetic brain exercise training. Kinesthetic brain exercises will be performed for 30 minutes, 2 days a week for 8 weeks. Demographic information of the individuals will be collected; age, gender, body mass index, age at diagnosis, ejection fraction ratio, family history, smoking status (years/pack). Cognitive function; The Montreal Cognitive Assessment Scale (MoCA), quality of life using the Minnesota Heart Failure Living Questionnaire, and cognitive performance using the Standardized Minimental Test (SMMT) will be used for evaluation. Biochemical analyses will be performed using the Brain-Derived Neurotrophic Factor (BDNF) ELISA kit. Patients in both groups will be evaluated by a physiotherapist before the study and at week 8.
- Conditions
- Heart
- Being tested
- Kinesthetic brain exercises, Cardiorespiratory Physiotherapy, Heart Failure drugs
- Keywords
- Heart failure, cognitive function
- Medical subject headings
- Heart Failure
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Kinesthetic brain exercisesOther
Kinesthetic brain exercises are a series of movements designed to connect the body and mind, encourage the use of brain hemispheres through physical and mental strategies, and also improve and strengthen cognitive functions for learning.
Cardiorespiratory PhysiotherapyOther
This is the standard physiotherapy procedure applied to patients with heart failure. It includes practices aimed at improving breathing, improving respiratory muscle strength, and providing mobilization. It encompasses breathing exercises, functional mobility exercises, stretching and flexibility exercises for the upper and lower extremities, etc.
Heart Failure drugsDrug
Continued use of medications prescribed by the cardiologist, under the supervision of the doctor.
| Study group | Role | What they receive |
|---|---|---|
| Exercise | Experimental | Not described Receives: Other: Kinesthetic brain exercises; Other: Cardiorespiratory Physiotherapy; Drug: Heart Failure drugs |
| Control | Active comparator | Not described Receives: Other: Cardiorespiratory Physiotherapy; Drug: Heart Failure drugs |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cognitive Function
Cognitive function will be assessed using the Montreal Cognitive Assessment Scale (MoCA). The MoCA was developed as a rapid screening test for mild cognitive impairment. The MoCA assesses various cognitive functions, including attention and concentration, executive functions, memory, language, visual construction skills, abstract thinking, calculation, and orientation. The test is scored between 0 and 30 points. A score of 21 or higher is considered normal.
Measured: Initially and after 8 weeks
Biochemical analyses
Brain-derived neurotrophic factor (BDNF) will be examined through biochemical analyses.
Measured: Initially and after 8 weeks
Cognitive Performance
The Standardized Mini-Mental Test (SMMT) will be used to assess cognitive performance. Test scores range from 0 to 30. The threshold for the Mini-Mental Test is 22-23 for educated individuals and 18-19 for uneducated individuals. In assessments for individuals with dementia, scores between 25-30 indicate normal cognitive function, 21-24 indicate mild dementia, 10-20 indicate mild-to-moderate dementia, and 0-9 indicate advanced dementia.
Measured: Initially and after 8 weeks
Secondary outcomes (1)
Quality of life in heart failure
Quality of life in heart failure will be assessed using the Minnesota Heart Failure and Life Questionnaire. This scale consists of 21 statements that specifically examine the quality of life in individuals with heart failure in terms of physical and emotional functioning. The sum of the answers to all 21 statements gives a total score ranging from 0 to 105. A lower score indicates a better quality of life.
Measured: Initially and after 8 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Feb 2026
- Study start11 Feb 2026
- Primary completion15 Apr 2026 (estimated)
- Study completion15 Oct 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HeartStudies of the same condition, open and under way.
- More trials run by Ege UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Ege University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ozden Gokcek, Ege University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07417748
- Sponsor's protocol ID
- 2026/02
- Status last verified
- Feb 2026
- First submitted
- 11 Feb 2026
- Last updated
- 20 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of Kinesthetic Brain Exercises on Cognitive Function in Patients With Heart Failure
- ClinicalTrials.gov ID
- NCT07417748
- Acronym / sponsor ID
- 2026/02
- Conditions
- Heart
- Keywords
- Heart failure, cognitive function
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Ege UniversityUniversity, hospital or other
- Study start
- 11 Feb 2026 (actual)
- Primary completion
- 15 Apr 2026 (estimated)
- Study completion
- 15 Oct 2026 (estimated)
- First posted
- 18 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to determine the possible effect of kinesthetic brain exercises on cognitive function in patients with heart failure.
The study will include 40 volunteer individuals aged 30-65 years who have been diagnosed with heart failure in the Cardiology Department and are followed up with a physiotherapy program. Individuals will be randomized into a kinesthetic brain exercise program group (n=20) and a control group (n=20).
The control group will receive routine medication monitoring as well as a routine physiotherapy program. The education group will receive routine medication monitoring and a routine physiotherapy program, in addition to individual kinesthetic brain exercise training. Kinesthetic brain exercises will be performed for 30 minutes, 2 days a week for 8 weeks. Demographic information of the individuals will be collected; age, gender, body mass index, age at diagnosis, ejection fraction ratio, family history, smoking status (years/pack). Cognitive function; The Montreal Cognitive Assessment Scale (MoCA), quality of life using the Minnesota Heart Failure Living Questionnaire, and cognitive performance using the Standardized Minimental Test (SMMT) will be used for evaluation. Biochemical analyses will be performed using the Brain-Derived Neurotrophic Factor (BDNF) ELISA kit. Patients in both groups will be evaluated by a physiotherapist before the study and at week 8.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Exercise | Experimental | Other: Kinesthetic brain exercises, Other: Cardiorespiratory Physiotherapy, Drug: Heart Failure drugs |
| Control | Active comparator | Other: Cardiorespiratory Physiotherapy, Drug: Heart Failure drugs |
Who may qualify
- Ages
- 30 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Diagnosed with heart failure
- Between 30-65 years of age
- No history of cardiac surgery
- Cooperative patients
Key exclusion criteria (5 listed)
- Diagnosed with or having a history of neurological disease
- Pregnant or suspected of being pregnant
- Scoring above 24 on the Mini Mental Test
- Patients for whom exercise is contraindicated
- Individuals with a history of orthopedic surgery
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Kinesthetic brain exercisesKinesthetic brain exercises are a series of movements designed to connect the body and mind, encourage the use of brain hemispheres through physical and mental strategies, and also improve and strengthen cognitive functions for learning. | Other | Exercise |
| Cardiorespiratory PhysiotherapyThis is the standard physiotherapy procedure applied to patients with heart failure. It includes practices aimed at improving breathing, improving respiratory muscle strength, and providing mobilization. It encompasses breathing exercises, functional mobility exercises, stretching and flexibility exercises for the upper and lower extremities, etc. | Other | Control, Exercise |
| Heart Failure drugsContinued use of medications prescribed by the cardiologist, under the supervision of the doctor. | Drug | Control, Exercise |
Primary outcome
Cognitive Function
Time frame: Initially and after 8 weeks
Cognitive function will be assessed using the Montreal Cognitive Assessment Scale (MoCA). The MoCA was developed as a rapid screening test for mild cognitive impairment. The MoCA assesses various cognitive functions, including attention and concentration, executive functions, memory, language, visual construction skills, abstract thinking, calculation, and orientation. The test is scored between 0 and 30 points. A score of 21 or higher is considered normal.
Biochemical analyses
Time frame: Initially and after 8 weeks
Brain-derived neurotrophic factor (BDNF) will be examined through biochemical analyses.
Cognitive Performance
Time frame: Initially and after 8 weeks
The Standardized Mini-Mental Test (SMMT) will be used to assess cognitive performance. Test scores range from 0 to 30. The threshold for the Mini-Mental Test is 22-23 for educated individuals and 18-19 for uneducated individuals. In assessments for individuals with dementia, scores between 25-30 indicate normal cognitive function, 21-24 indicate mild dementia, 10-20 indicate mild-to-moderate dementia, and 0-9 indicate advanced dementia.
1 secondary outcome
Quality of life in heart failure
Time frame: Initially and after 8 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Feb 2026.
- Individual participant dataSharing planned: No
Related trials for Heart
RecruitingPhase 4
The Impact of Perioperative Lidocaine Infusions on Enhanced Recovery After Non-Cardiac Surgery
Pain, Post Operative Analgesia
Not yet recruitingPhase 4
An Investigator-initiated, Prospective, Open-label, Multicenter Randomized Controlled Trial, Comparing the Efficacy of Sacubitril/Valsartan and Standard Treatment on Atrial Fibrillation Recurrence After Catheter Ablation in Persistent Atrial Fibrillation Patients Without Hypertensive
Atrial Fibrillation (Persistent), Catheter Ablation
Not yet recruiting
LBBAP Versus ILR in Patients With New-Onset LBBB and Moderately Reduced LVEF After TAVI
TAVI(Transcatheter Aortic Valve Implantation), Left Bundle Branch Block
Recruiting
Reducing Fluid Overload in Heart Failure Patients Using a Non-invasive, Renal Independent System
Chronic Heart Failure, CKD Stage 3
Recruiting
Tricuspid Regurgitation Treatment With LAPLACE Transcatheter Tricuspid Valve Replacement System
Severe Tricuspid Valve Regurgitation, Tricuspid Valve Regurgitation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Kinesthetic brain exercises, Cardiorespiratory Physiotherapy and Heart Failure drugs in people with Heart, run by Ege University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 20 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cognitive Function (time frame: Initially and after 8 weeks). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Feb 2026.